Susan G. MacDonald

Sue is Vice President, R&D Strategy & Program Management at Parthenon. She is an experienced biotech executive with more than 25 years of experience in research and development, spanning several therapeutic areas and therapeutic modalities. Her expertise includes basic and translational research, leading cross-functional discovery and development programs, developing strategies for projects and portfolios, and alliance management. She has deep experience in preparing and submitting INDs/CTAs, including meeting with regulatory agencies in North America and Europe, and in the development of strategies for programs through registration. She most recently served as Vice President of Research and Development at Aldeyra Therapeutics. Prior to joining Aldeyra, she held senior roles in R&D Strategy, Portfolio, and Project Management at Alexion Pharmaceuticals and Program Management at NKT Therapeutics. She has also served in a variety of roles at Archemix, ArQule, TEI Biosciences, and Onyx Pharmaceuticals, where, as a founding employee, she conducted research that enabled the discovery of sorafenib (Nexavar®). Sue also advises and helps emerging companies navigate the intersecting paths of strategy, science, and development.

Sue received her undergraduate degree in biology from Hobart and William Smith Colleges and her Ph.D. in Physiology from the University of Massachusetts Medical School. She completed her postdoctoral training at Onyx Pharmaceuticals, during which she received a prestigious NIH National Research Service Award.